NCT03064854 - PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

PDR001

Powder for solution for infusion

DRUG

Cisplatin

Intravenous infusion

DRUG

Gemcitabine

Intravenous infusion

DRUG

Pemetrexed

Intravenous infusion

DRUG

Carboplatin

Intravenous infusion

DRUG

Paclitaxel

Intravenous infusion

DRUG

Canakinumab

Subcutaneous injection

Trial Locations (23)

3000

Novartis Investigative Site, Leuven

8800

Novartis Investigative Site, Roeselare

13885

Novartis Investigative Site, Marseille

20089

Novartis Investigative Site, Rozzano

28034

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

33081

Novartis Investigative Site, Aviano

37075

Novartis Investigative Site, Göttingen

47014

Novartis Investigative Site, Meldola

48202

Henry Ford Health System SC, Detroit

51109

Novartis Investigative Site, Cologne

63110

Washington University School of Medicine SC, St Louis

69373

Novartis Investigative Site, Lyon

72703

Highlands Oncology Group, Fayetteville

90404

UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica

94305

Stanford Cancer Center SC, Stanford

169610

Novartis Investigative Site, Singapore

M5G 2M9

Novartis Investigative Site, Toronto

140 59

Novartis Investigative Site, Prague

Unknown

Novartis Investigative Site, Pokfulam

1066 CX

Novartis Investigative Site, Amsterdam

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona